Bortezomib ocular toxicities: Outcomes with ketotifen

Am J Hematol. 2019 Mar;94(3):E80-E82. doi: 10.1002/ajh.25382. Epub 2019 Jan 3.

Authors

Michael Dennis¹, Asaf Maoz¹, David Hughes², Vaishali Sanchorawala², J Mark Sloan², Shayna Sarosiek²

Affiliations

¹ Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts.
² Section of Hematology & Medical Oncology, Department of Medicine, Boston University School of Medicine and Boston Medical Center, Boston, Massachusetts.

PMID: 30575098
DOI: 10.1002/ajh.25382

No abstract available

Publication types

Letter

MeSH terms

Adult
Aged
Amyloidosis / drug therapy
Amyloidosis / pathology
Antineoplastic Combined Chemotherapy Protocols / adverse effects*
Bortezomib / administration & dosage
Bortezomib / adverse effects*
Chalazion / chemically induced
Chalazion / drug therapy*
Chalazion / physiopathology
Conjunctivitis / chemically induced
Conjunctivitis / drug therapy*
Conjunctivitis / physiopathology
Female
Histamine H1 Antagonists / therapeutic use*
Humans
Ketotifen / therapeutic use*
Male
Middle Aged
Multiple Myeloma / drug therapy
Multiple Myeloma / pathology
Ophthalmic Solutions / therapeutic use
Retrospective Studies
Treatment Outcome

Substances

Histamine H1 Antagonists
Ophthalmic Solutions
Bortezomib
Ketotifen